Deregulated activation of the KIT receptor tyrosine kinase has been implicated in several human cancers and in inflammation, making it an attractive target for therapeutic intervention. Conversely, deficiencies in KIT signaling have been implicated in human and animal hair pigmentation disorders, reflecting a role for KIT in the development and function of melanocytes. The goal of this study was to explore the potential utility of hair depigmentation as a biological readout for systemic inhibition of KIT by SU11248 5-
seen after administration of a KIT-neutralizing antibody. SU11248-induced hair depigmentation was reversible with cessation of treatment. Histological and immunohistochemical evaluation of mouse skin samples supported these observations and revealed that SU11248 has no effect on levels of KIT-positive melanocytes associated with hair follicles, indicating that the inhibitory effect is at the level of melanocyte function rather than their development/survival. Similar hair depigmentation has been noted in several cancer patients receiving SU11248 in phase I trials. Strikingly, patient scalp hair exhibits bands of depigmentation and pigmentation that correspond, respectively, to periods of treatment and dosing rest periods. These data demonstrate that hair pigmentation can serve as a dose-dependent, dynamic, biological readout for KIT inhibition in mice, and, apparently, in humans.
KIT activation has been implicated in a number of human cancers, including mastocytosis, germ cell tumors, small-cell lung carcinoma, gastrointestinal stromal tumors, acute myelogenous leukemia, neuroblastoma, melanoma, ovarian carcinoma, and breast carcinoma (Turner et al., 1992; Heinrich et al., 2002) . KIT activation in these tumors is generally accomplished by one or more of three mechanisms: autocrine and/or paracrine stimulation by stem cell factor (SCF, the ligand for KIT), cross-activation by other kinases, and the acquisition of activating mutations (Hirota et al., 1998; Heinrich et al., 2002) . Based on these data, KIT is under active development as an oncology target. Most notably, Gleevec (Novartis, Basel, Switzerland), a selective inhibitor of BcrAbl, KIT, and platelet-derived growth factor (PDGF) receptor ␤, has been approved for the treatment of malignant metastatic and/or unresectable gastrointestinal stromal tumors (Dagher et al., 2002) . In addition to its role in cancer, KIT activation has also been implicated in inflammation (Krishnaswamy et al., 2001) .
In contrast to the role of KIT up-regulation in cancer and inflammation, many white spot or band coat color patterns in mammals have been traced to loss-of-function mutations in the genetic loci dominant white spotting (W) and steel (Sl), which encode, respectively, KIT and SCF (Chabot et al., 1988; Zsebo et al., 1990; Halaban and Moellmann, 1993) . Specifically, gene duplication and splice mutations in W are responsible for the white coat color in Large White pigs, whereas an inversion mutation in W presents the Rump White color pattern in mice (Stephenson et al., 1994; Marklund et al., 1998) . Similarly, piebaldism, a rare human autosomal dominant disorder of melanocyte development, has been traced to a number of point, deletion, splice, and insertion mutations in the W locus (Richards et al., 2001) .
The hair follicle passes through three key cyclic regeneration stages, telogen, anagen, and catagen, of which anagen is the most significant for pigmentation (Paus and Cotsarelis, 1999) . Pigment for the hair shaft is generated solely by the follicular melanocytes, which reside above the dermal papilla next to the keratinocytes. The keratinocytes take up pigment from the melanocytes and incorporate it into the growing hair shaft (Tobin et al., 1999; Scott et al., 2002) . During early anagen, SCF/KIT signaling is vitally important for both melanocyte proliferation/differentiation and proper pigment production. Without SCF/KIT signaling during anagen, melanocytes are absent or unable to pass melanin to the growing keratinocytes (Botchkareva et al., 2001) . The end result is a hair follicle partially or completely devoid of color.
It has been previously demonstrated that intradermal injection of ACK45, a KIT-neutralizing monoclonal antibody, during the anagen cycle of hair follicle regeneration will prevent pigmentation of the hair shaft (Botchkareva et al., 2001) . SU11248 is a small molecule inhibitor of Class III/V receptor tyrosine kinases including the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, KIT and FLT3, and is highly selective for these kinases over other kinases evaluated Mendel et al., 2003; O'Farrell et al., 2003) Here we show that systemically administered SU11248 induces reversible hair depigmentation in mice. Moreover, SU11248 treatment has resulted in reversible loss of hair pigmentation in a number of cancer patients enrolled in Phase I studies. These data directly demonstrate that the enzymatic activity of KIT is required for development and maintenance of appropriate hair pigmentation in mice and humans. In addition, these results demonstrate the feasibility of using hair pigmentation as a biological readout for KIT inhibition in preclinical drug discovery and in the clinic.
Materials and Methods
Animals and Tissue Collection. Female C57BL/6 mice (6 -8 weeks old) were purchased from Charles River (Hollister, CA) and housed in sterile filter-top cages with Aspen Chip bedding on HEPAfiltered ventilated racks. Animals received sterile rodent chow and water ad libitum and were kept under 12-h light/dark cycles. Animal experiments were conducted in accordance to Institutional Animal Care and Use Committee guidelines in the SUGEN, Inc. Animal Facility, which has been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
To induce the hair cycle, depilation of skin on the back of mice was performed as described previously (Paus et al., 1990) . Briefly, hair was removed from anesthetized mice using Nair's cold wax hair removal kit as per kit instructions. SU11248 was administered orally as described previously (Mendel et al., 2003) , with the first dose administered 4 h before depilation. The rat anti-mouse KIT-neutralizing monoclonal antibody ACK2 (Nishikawa et al., 1991) was purchased from eBioscience (San Diego, CA) and administered intraperitoneally twice weekly in a PBS vehicle. On day 21 to 28 (depending on the study), animals were sacrificed and analyzed for pigmentation of the regenerated hair shaft. Skin was harvested parallel to the vertebral line and fixed in Streck tissue fixative (Streck Laboratories, Omaha, NE) for immunohistochemical analyses. In one study, a limited number of animals were taken off treatment on day 28 and replucked on day 30 to monitor repigmentation during hair regrowth.
Immunohistochemisty. Streck-fixed skin was paraffin-embedded and sectioned. General tissue morphology was visualized by H&E staining. Slides were immunostained for KIT using a rabbit polyclonal anti-KIT antibody (A-4502 1:25; DAKO, Glostrup, Denmark). This antibody was affinity purified through antigen-bound activated thiol AvidGel F chromatography, based on package insert information supplied by the manufacturer. Secondary detection was by a horseradish peroxidase-labeled polymer conjugated to antirabbit antibodies (EnVisionϩ Systems; DAKO).
Results
In a pilot experiment, the ability of oral SU11248 administered once daily at 80 mg/kg to inhibit pigmentation of hair newly regrown after depilation was assessed. As a positive control (Yoshida et al., 1997) , the KIT-neutralizing antibody ACK2 was administered IP twice weekly at 300 g, 150 g, and 50 g per animal (n ϭ 3 mice for all treatment groups). Three weeks later, ACK2 animals showed complete whitening of hair at 300 g, graying at 150 g and no depigmentation at 50 g. SU11248-treated mice exhibited hair depigmentation comparable to animals treated with ACK2 at 300 g (Fig. 1) .
To explore the dose-responsiveness of depigmentation associated with SU11248 treatment, SU11248 was administered at 80 or 40 mg/kg once daily in this model (n ϭ 5 mice per group). As before, SU11248 treatment at 80 mg/kg resulted in whitening of regrown coat hair. In contrast, treatment at 40 mg/kg generally resulted in moderate graying of regrown coat hair (Fig. 2) . Similar results were obtained in additional studies, which also determined that treatment at 20, and 5 mg/kg once daily had no detectable effect on hair pigmentation (data not shown). Selected mice were removed from treatment on day 28 for the study shown in Fig. 2 and depilated a second time on day 30. By day 52, these mice showed regrowth of completely pigmented hair (Fig. 3) , demonstrating the reversibility of this effect.
Skin samples of control and treatment animals were taken for histological evaluation. Hair pigmentation was clearly evident in hematoxylin and eosin (H&E)-stained slides from control animals; however, only translucent (white) hair was evident in skin samples from animals that had been treated with SU11248 at 80 mg/kg (Fig. 4) . Gray hairs of varying shades predominated in H&E-stained slides of animals treated with SU11248 at 40 mg/kg (Fig. 4) . To determine whether depigmentation was mediated via loss of KIT-positive cells in hair follicles, immunostaining for KIT was performed. The presence of KIT-positive cells, presumably melanocytes, was clearly evident in the hair follicles of both vehicle and SU11248-treated mice (Fig. 5) .
Interestingly, loss of hair pigmentation has been noted in a number of patients with advanced cancer enrolled in SU11248 clinical trials. A striking example of this from a phase I trial being conducted in Australia is shown in Fig. 6 , which shows an 18-year-old male patient with chemotherapy-refractory metastatic synovial sarcoma who underwent treatment with SU11248. This patient received multiple 6-week cycles of treatment, with each cycle comprising a 4-week period receiving SU11248 and a 2-week break from treatment. The patient exhibited loss of hair pigmentation while receiving SU11248, but his hair became repigmented during breaks from treatment. Five cycles of treatment resulted in his hair exhibiting multiple light/white and dark bands, with the light bands, as anticipated, being longer than the dark bands (Fig. 6) . Similar reversible hair depigmentation by SU11248 has recently been reported in multiple patients from a phase I study in France .
Discussion
We have demonstrated that treatment with SU11248 resulted in inhibition of hair pigmentation in mice and humans. This effect was fully reversible, being lost when SU11248 treatment was discontinued. In our mouse model, hair pigmentation was modulated in a dose-dependent, quasi-analog manner, i.e., individual hairs were either white, black, or varying shades of gray. Although the most spectacular effects were seen in regions of hair that had been plucked, isolated white hairs were also evident in nonplucked regions of mice, notably their muzzles ( Figs. 1 and 2 ; data not shown). Barbering, the removal of hair and whiskers by dominant mice, may provide an explanation for this observation. Barbering entails the plucking of individual hairs, which would duplicate, on an individual level, the regional hair plucking performed in this study (Sarna et al., 2000) .
Previous studies using KIT-neutralizing antibodies have demonstrated effects on both melanocyte differentiation and survival in mice (Yoshida et al., 1996; Botchkareva et al., 2001) . The black mice used in all of these studies were immunocompetent, complicating interpretation of the effects of KIT neutralizing antibodies, which could potentially immunologically target cells on the basis of KIT positivity in addition to simply inhibiting KIT function. In contrast, the effects seen with SU11248 in this model are presumably mediated via inhibition of KIT kinase activity. Although it is not a specific inhibitor of KIT, SU11248 is highly selective for class III/V receptor tyrosine kinases, including KIT, over other kinases evaluated (Mendel et al., 2003) . Potential downstream effectors of KIT signaling in this pathway include the transcription factors Mi and Slug (Wu et al., 2000; PerezLosada et al., 2002) .
No change in levels of KIT positive cells in mouse hair follicles was observed (Fig. 5) , indicating that the inhibitory effect on pigmentation documented here is likely mediated at the level of function. Consistent with this, when treatment with SU11248 was halted and mice were replucked they regrew black hair (Fig. 3) . This effect does not result from the hair becoming refractory to depigmentation per se, because Hair depigmentation has been reported in a number of patients receiving SU11248 in clinical trials Robert et al., 2003; Toner et al., 2003) . Most commonly, this is reported as the development of white or gray hair. Depigmentation in human patients is reversible at the level of individual hair follicles, with both pigmentation and depigmentation evident on the same hair shafts, as seen in the patient shown in Fig. 6 , and in at least several additional cases ; data not shown). The presence of the pigmented bands of hair, which grow during breaks in administration of SU11248, presumably reflects the recovery of KIT activity during treatment breaks, as well as the original hair color.
In mice, depigmentation was complete when SU11248 was administered at 80 mg/kg once daily. In humans, depigmentation was evident in some patients from phase I studies treated once daily with 50 mg of SU11248 (now the recommended phase II dose) or higher doses ; Fig. 3 . Reversibility of SU11248-induced hair depigmention. On day 28 an animal was removed from treatment (SU11248 at 80 mg/kg). On day 30, this animal was again depilated and its coat allowed to regrow without drug treatment. Final evaluation on day 52 revealed a completely repigmented coat. Fig. 4 . SU11248 treatment results in dose-dependent loss of pigmentation at the level of individual hairs. Dorsal skin was taken at the end of the study shown in Fig. 2 , fixed, and H&E stained (images shown at 400ϫ magnification; hairs indicated with arrows). Regrown hair from mice treated at 80 mg/kg was uniformly translucent (white), whereas that taken from mice treated at 40 mg/kg was of varying shades of gray (two light, one dark). These images are representative of 20 to 25 fields evaluated for each of three to four animals per group. 6 . SU11248 inhibits hair pigmentation in humans. Images of an 18-year-old male with metastatic synovial sarcoma undergoing treatment with SU11248 at the Peter MacCallum Cancer Institute (Victoria, Australia) are shown (lower panel is at higher magnification to show more detail of pigmentation pattern). This patient received multiple 6-week cycles of treatment, with each cycle comprising a 4-week period receiving SU11248 and a 2-week break from treatment. Treatment was initiated at 50 mg given orally once daily (subsequently identified as recommended phase II dose). After three cycles, the dose was reduced to 50 mg orally on alternate days. Cyclical hair depigmentation is evident that was concordant with the treatment regimen. Depigmented bands of hair grown during periods when the patient was receiving SU11248 (white arrows) are distinct from pigmented bands of hair grown during drug-free breaks (black arrows).
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at ASPET Journals on April 7, 2017 jpet.aspetjournals.org Downloaded from Toner et al., 2003) . In terms of time above target plasma concentration (50 -100 ng/ml), the exposure seen in mice at 80 mg/kg/day is roughly comparable with that seen in humans at 50 to 75 mg/day. However, pharmacokinetic differences for SU11248 between mice and humans (compare Mendel et al., 2003 with Washington et al., 2003 and our current incomplete understanding of the pharmacokinetic/pharmacodynamic relationship underlying hair depigmentation make it difficult to make quantitative cross-species comparisons for this phenomenon.
In mice, treatment with SU11248 at 40 mg/kg once daily resulted in substantial inhibition of KIT phosphorylation and hair pigmentation, whereas treatment at 80 mg/kg once daily resulted in complete inhibition of KIT phosphorylation and hair pigmentation. In contrast, 40 mg/kg given once daily is generally sufficient for full antitumor efficacy in mouse models (Mendel et al., 2003) . These data are consistent with previous observations that the target plasma inhibitor concentrations for SU11248 for the VEGF and PDGF receptors (primary targets in most cancer models) is 50 to 100 ng/ml (Mendel et al., 2003) , whereas the target plasma concentration for KIT may be somewhat higher . Hence, although loss of hair pigmentation in treated mice and human patients should be solely indicative of inhibition of KIT, simultaneous inhibition of other class III/V receptor tyrosine kinase targets of SU11248, such as the VEGF and PDGF receptors, and FLT3, can be inferred.
Treatment with Gleevec (Novartis), a selective inhibitor of several tyrosine kinases, including KIT, Bcr-Abl, and PDGF receptor ␤, has been associated with depigmentation of skin of at least one chronic myelogenous leukemia patient (Raanani et al., 2002) . Interestingly, treatment with Gleevec has also been reported to induce progressive repigmentation of gray hair in a small number of patients (Etienne et al., 2002) . In addition to the hair depigmentation effects we have documented here with SU11248, we have also noted that the repigmented bands of patient hair evident during rest periods off SU11248 are sometimes darker than the original patient hair color (data not shown). The mechanistic basis underlying this phenomenon is as yet unknown and will require further study.
Use of hair color as a readout in patients is dependent on the presence of a high basal level of hair pigmentation and is hence likely to be of most utility in dealing with younger patients (such as the patient shown in Fig. 6 ). In conclusion, we have identified hair depigmentation as a dynamic, noninvasive biological biomarker of KIT modulation in mice and humans.
